‘Sec. 3. 22 MRSA §7250, sub-§4, ¶I is enacted to read:
I. A law enforcement agency with the written approval of the Attorney General or of the District Attorney for the jurisdiction in which the investigation is pending, insofar as the information relates to an active criminal investigation involving a prescription drug offense. Prescription monitoring information in the possession or under the control of a law enforcement agency is confidential and may be disseminated only in accordance with Title 16, section 614. The department shall accommodate requests for prescription monitoring information properly executed by law enforcement agencies pursuant to this paragraph. The department, in consultation with the Attorney General, shall adopt rules regarding requests by law enforcement agencies for prescription monitoring information, which must be made to the director of the program. Rules adopted pursuant to this paragraph are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A.’